Johnson & Johnson's Type 2 Diabetes Drug Is Stellar in Cardiovascular Trials, but Comes With a Catch - Motley Fool

Motley Fool

Johnson & Johnson's Type 2 Diabetes Drug Is Stellar in Cardiovascular Trials, but Comes With a Catch Motley Fool SGLT-2 inhibitors don't work in the pancreas and liver as traditional type 2 diabetes medications do. Instead, SGLT-2 inhibitors like Invokana block the absorption of glucose in the kidneys and promote glycemic balance by allowing the body to rid ... and more »